Beth Hoffman

Founder & CEO of Origami Therapeutics, Inc. (YC W22)

Origami Therapeutics, Inc.· Winter 2022🇺🇸 San Diego, California, United States

in LinkedIn 𝕏 @bethjhoffman

2021Member, Tau Consortium Scientific Advisoy Board· The Rainwater Charitable Foundation

In tech · since 1988

Company

The Rainwater Charitable Foundation

Role

Member, Tau Consortium Scientific Advisoy Board

current

Stage

—

no public source

Raised

—

no public source

Based

—

Founder / co-founder — the company's markEmployee / research role

Source: LinkedIn work history

Profile coverage5 of 7 · missing posts, contact

Origami Therapeutics, Inc.

Oral drugs to halt neurodegeneration

Winter 2022

Experience

Career

Origami Therapeutics, Inc.
CEO · Greater San Diego Area · 2015 – Present
2015
Biofrontera Inc.
Member Board Of Directors · Massachusetts, United States · 2021 – Present
2021
The Rainwater Charitable Foundation
Member, Tau Consortium Scientific Advisoy Board · 2021 – Present
2021
Vertex Pharmaceuticals, Inc.
Vice President, Discovery Biology · Greater San Diego Area · 2007 – 2014
2007
Amgen, Inc.
Scientific Executive Director, Neuroscience · Greater Los Angeles Area · 2004 – 2006
2004
Eli Lilly & Co
Head, Neuroscience · Indianapolis, Indiana Area · 1998 – 2004
1998
National Institute of Mental Health
Head, Unit on Molecular Pharmacology · Greater Washington, DC Area · 1988 – 1998
1988

Bio

At Origami Therapeutics, Dr. Hoffman is creating a new approach to drug discovery for neurodegenerative diseases. Prior to Origami, she was a Research & Development executive at Vertex Pharmaceuticals, Amgen and Eli Lilly. She has made major contributions to >30 clinical programs in neurology, pain and psychiatry and to four marketed drugs for Cystic Fibrosis. Dr. Hoffman received her A.B. in Molecular Biology from Wellesley College and a Ph.D. in Cell Biology from the Johns Hopkins University.